Dr Reddy Q1 net dips as costs, competition hurts
Facebook Twitter google+ RSS Feed

Dr Reddy Q1 net dips as costs, competition hurts

By siliconindia staff writer   |   Wednesday, 28 July 2004, 07:00 Hrs
Printer Print Email Email
MUMBAI: Indian drug maker Dr Reddy's Laboratories reported on Tuesday its quarterly net profit fell on high research and development costs, growing competition and a lack of big drug launches.
The Hyderabad-based firm said its first-quarter net profit according to Indian accounting standards, fell to Rs 309.4 million ($7 million) from Rs 1.2 billion reported a year earlier.

Dr Reddy's, India's only New York Stock Exchange-listed drug firm, is one of a handful of Indian generic drug makers to have made headway in the developed pharma markets of the United States and Europe.

Ahead of the results, Dr Reddy's shares closed 0.26 per cent up at the Bombay Stock Exchange. The stock has lost 47 per cent from the start of 2004, underperforming the Bombay Stock Exchange's Healthcare index's 10 per cent losses and the broader Bombay Stock Exchange index's 12 per cent losses.



Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Philips
Sr. Executive
ISB
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
NIC
Reena Khanna
Founder
Solitaireworld
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset
SPOTLIGHT